ADReCS

Pharmaceutical Information

Drug Name	Prednisolone
Drug ID	BADD_D01831
Description	Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects.[A187463] Prednisolone was granted FDA approval on 21 June 1955.[L9431]
Indications and Usage	Prednisolone is indicated to treat endocrine, rheumatic, and hematologic disorders; collagen, dermatologic, ophthalmic, respiratory, and gastrointestinal diseases; allergic and edematous states; and other conditions like tuberculous meningitis.[L9542]
Marketing Status	approved; vet_approved
ATC Code	A01AC04; A07EA01; C05AA04; D07AA03; D07XA02; H02AB06; R01AD02; S01BA04; S01CB02; S02BA03; S03BA02
DrugBank ID	DB00860
KEGG ID	D00472
MeSH ID	D011239
PubChem ID	5755
TTD Drug ID	D0D1SG
NDC Product Code	38779-0150; 64958-0097; 82298-104; 67296-1656; 50383-042; 59651-491; 63187-466; 0527-5406; 65089-0038; 50090-0655; 57582-004; 62135-437; 73534-505; 49452-5980; 82298-105; 82298-106; 60592-911; 60722-3001; 51927-0234; 22552-0052
UNII	9PHQ9Y1OLM
Synonyms	Prednisolone \| Predate \| Predonine \| Di-Adreson-F \| Di Adreson F \| DiAdresonF

Chemical Information

Molecular Formula	C21H28O5
CAS Registry Number	50-24-8
SMILES	CC12CC(C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C)O
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Hypothalamic pituitary adrenal axis suppression	05.03.04.007	0.000070%		-
Foetal heart rate deceleration abnormality	02.03.02.022; 18.03.02.012	0.000035%		-
Faeces soft	07.01.03.008	0.000052%		-
Encapsulating peritoneal sclerosis	07.07.03.004	0.000087%		-
Mouth swelling	07.05.04.007; 10.01.05.020; 23.04.01.020	0.000035%		-
Intrusive thoughts	19.10.03.008	0.000052%		-
Multiple organ dysfunction syndrome	08.01.03.057	0.001066%
Agitated depression	17.02.05.050; 19.15.01.007	0.000035%		-
Antiphospholipid syndrome	01.01.02.016; 10.04.01.009; 18.02.04.002; 24.01.01.029	0.000035%		-
Behcet's syndrome	06.04.05.017; 07.05.06.008; 10.02.02.015; 15.01.01.009; 21.10.03.009; 23.06.02.004; 24.12.04.003	0.000140%		-
Bladder transitional cell carcinoma	16.08.01.002; 20.03.04.003	0.000035%		-
Brief psychotic disorder, with postpartum onset	18.06.03.001; 19.03.05.002	0.000035%		-
Bronchial fistula	22.03.02.011	0.000070%
Carotid artery aneurysm	17.08.06.002; 24.02.04.003	0.000035%		-
Central nervous system lymphoma	01.12.01.005; 16.20.01.005; 17.02.10.028; 18.04.04.013	0.000052%		-
Cholangitis acute	09.02.01.006	0.000035%		-
Chronic gastritis	07.08.02.005; 10.04.04.011; 11.07.01.016	0.000035%		-
Concomitant disease aggravated	08.01.03.063	0.000052%		-
Diverticulum intestinal haemorrhagic	07.10.01.003; 24.07.02.043	0.000035%		-
Fracture nonunion	12.04.02.017; 15.08.01.004	0.000105%		-
Hallucination, olfactory	19.10.04.005	0.000052%		-
Hepatic infarction	09.01.06.017; 24.04.07.007	0.000070%		-
IgA nephropathy	10.02.01.063; 20.05.01.016	0.000035%		-
Ileal stenosis	07.13.06.006	0.000052%
Impulsive behaviour	19.18.01.001	0.000087%		-
Intestinal fistula	07.11.05.012	0.000105%		-
Joint destruction	15.01.08.012	0.000035%		-
Lichen sclerosus	21.10.03.010; 23.03.08.006	0.000070%		-
Lupus nephritis	10.04.03.011; 15.06.02.011; 20.05.02.003	0.000070%		-
Metastases to lymph nodes	01.09.01.015; 16.22.02.006	0.000052%		-

The 29th Page First Pre 29 30 31 32 33 Next Last Total 36 Pages